Pushing healthcare forward requires us to propel medicines to their full potential. We make possible what others consider impossible. Take a look at our product portfolio to see what the right mix of technology and heart can accomplish.

RYANODEX® (dantrolene sodium) for injectable suspension

RYANODEX® is indicated for the treatment of malignant hyperthermia in conjunction with appropriate supportive measures, and for the prevention of malignant hyperthermia in patients at high risk.1

DOCETAXEL INJECTION (non-alcohol formula)

Docetaxel Injection is a microtubule inhibitor indicated for3:
Breast Cancer (BC): single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC
Non-Small Cell Lung Cancer (NSCLC): single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC
Hormone Refractory Prostate Cancer (HRPC): with prednisone in androgen independent (hormone refractory) metastatic prostate cancer
Gastric Adenocarcinoma (GC): with cisplatin and fluorouracil for untreated, advanced GC, including the gastroesophageal junction
Squamous Cell Carcinoma of the Head and Neck Cancer (SCCHN): with cisplatin and fluorouracil for induction treatment of locally advanced SCCHN

BENDEKA® (bendamustine hydrochloride) injection

BENDEKA® is an alkylating drug indicated for the treatment of patients with2:

  • Chronic lymphocytic leukemia (CLL). Efficacy relative to first-line therapies other than chlorambucil has not been established
  • Indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen

Argatroban Injection is a direct thrombin inhibitor indicated4:

  • For prophylaxis or treatment of thrombosis in adult patients with heparin-induced thrombocytopenia (HIT)
  • As an anticoagulant in adult patients with or at risk of HIT undergoing percutaneous coronary intervention (PCI)


We believe that making the best end product
starts at the beginning. This is why we use our
3-step process of reinvention to see products
through from start to finish.


Identify medicines that can benefit from second generation advancements


Improve products by determining the technology requirements to address unmet needs


Impact patients’ lives with improved medicines brought to market primarily through the 505(b)(2) regulatory pathway

Through a fully integrated commercial team, we have the flexibility to market our products with or without a partner.


  1. RYANODEX (dantrolene sodium) for injectable suspension [package insert]. Woodcliff Lake, NJ: Eagle Pharmaceuticals, Inc.; 2016.
  2. BENDEKA (bendamustine hydrochloride) injection [package insert]. North Wales, PA: Teva Pharmaceuticals USA, Inc.; 2017.
  3. DOCETAXEL INJECTION (non-alcohol formula) [package insert]. Woodcliff Lake, NJ: Eagle Pharmaceuticals, Inc.; 2016.
  4. Argatroban Injection [package insert]. Parsippany, NJ: The Medicines Company; 2016.